QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.080564v1 314/1/1    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rigas, B. Articles by Kashfi, K. Search for Related Content PubMed PubMed Citation Articles by Rigas, B. Articles by Kashfi, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer

PERSPECTIVES IN PHARMACOLOGY

Cancer Prevention: A New Era beyond Cyclooxygenase-2

Division of Cancer Prevention, Department of Medicine, The State University of New York at Stony Brook, Stony Brook, New York (B.R.); and Department of Physiology and Pharmacology, City University of New York Medical School, New York, New York (K.K.)

The seminal epidemiological observation that nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon and possibly other cancers has spurred novel approaches to cancer prevention. The known inhibitory effect of NSAIDs on the eicosanoid pathway prompted studies focusing on cyclooxygenase (COX) and its products. The increased prostaglandin E₂ levels and the overexpression of COX-2 in colon and many other cancers provided the rationale for clinical trials with COX-2 inhibitors for cancer prevention or treatment. Their efficacy in the prevention of sporadic colon and other cancers remains unknown; one COX-2 inhibitor has been withdrawn because of side effects, and there are concerns about whether these effects are class-specific. There is evidence to suggest that COX-2 may not be the only or ideal eicosanoid pathway target for cancer prevention. Six sets of observations support this notion: the relatively late induction of COX-2 during carcinogenesis; the finding that NSAIDs may not require inhibition of COX-2 for their effect; the modest effect of coxibs in cancer prevention; that currently available coxibs have multiple non-COX-2 effects that may account for at least some of their efficacy; the possibility that concurrent inhibition of COX-2 in non-neoplastic cells may be harmful; and the possibility that COX-2 inhibition may modulate alternative eicosanoid pathways in a way that promotes carcinogenesis. Given the limitations of COX-2-specific inhibitors and the biological evidence mentioned above, we suggest that targets other than COX-2 should be pursued as alternative or complementary approaches to cancer prevention.

Address correspondence to: Dr. Basil Rigas, Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794-8160. E-mail: basil.rigas{at}sunysb.edu

This article has been cited by other articles:

				Y. Sun, J. Chen, and B. Rigas Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death Carcinogenesis, January 1, 2009; 30(1): 93 - 100. [Abstract] [Full Text] [PDF]

				Y. Bren-Mattison, A. M. Meyer, V. Van Putten, H. Li, K. Kuhn, R. Stearman, M. Weiser-Evans, R. A. Winn, L. E. Heasley, and R. A. Nemenoff Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-{gamma} in Non-Small-Cell Lung Cancer Cells Are Mediated by Suppression of Cyclooxygenase-2 via Inhibition of Nuclear Factor-{kappa}B Mol. Pharmacol., March 1, 2008; 73(3): 709 - 717. [Abstract] [Full Text] [PDF]

				X. Zhao, M. Goswami, N. Pokhriyal, H. Ma, H. Du, J. Yao, T. A. Victor, K. Polyak, C. D. Sturgis, H. Band, et al. Cyclooxygenase-2 Expression during Immortalization and Breast Cancer Progression Cancer Res., January 15, 2008; 68(2): 467 - 475. [Abstract] [Full Text] [PDF]

				M. A. McIlhatton, J. Tyler, S. Burkholder, J. Ruschoff, B. Rigas, L. Kopelovich, and R. Fishel Nitric Oxide Donating Aspirin Derivatives Suppress Microsatellite Instability in Mismatch Repair Deficient and Hereditary Nonpolyposis Colorectal Cancer Cells Cancer Res., November 15, 2007; 67(22): 10966 - 10975. [Abstract] [Full Text] [PDF]

				M. B. Gillespie, M. W. Moody, F.-S. Lee, L. J. Poole, J. D. Hornig, D. Lathers, M. R. Young, and T. A. Day Head and Neck Cancer Recurrence and Mortality in Nonselective Cyclooxygenase Inhibitor Users Arch Otolaryngol Head Neck Surg, January 1, 2007; 133(1): 28 - 31. [Abstract] [Full Text] [PDF]

				M. Ding, R. Feng, S. Y. Wang, L. Bowman, Y. Lu, Y. Qian, V. Castranova, B.-H. Jiang, and X. Shi Cyanidin-3-glucoside, a Natural Product Derived from Blackberry, Exhibits Chemopreventive and Chemotherapeutic Activity J. Biol. Chem., June 23, 2006; 281(25): 17359 - 17368. [Abstract] [Full Text] [PDF]

				G.-S. Liu, L.-F. Liu, C.-J. Lin, J.-C. Tseng, M.-J. Chuang, H.-C. Lam, J.-K. Lee, L.-C. Yang, J. H. Y. Chan, S.-L. Howng, et al. Gene Transfer of Pro-opiomelanocortin Prohormone Suppressed the Growth and Metastasis of Melanoma: Involvement of {alpha}-Melanocyte-Stimulating Hormone-Mediated Inhibition of the Nuclear Factor {kappa}B/Cyclooxygenase-2 Pathway Mol. Pharmacol., February 1, 2006; 69(2): 440 - 451. [Abstract] [Full Text] [PDF]

				K. R. G. Knight, D. F. Kraemer, and E. A. Neuwelt Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development J. Clin. Oncol., December 1, 2005; 23(34): 8588 - 8596. [Abstract] [Full Text] [PDF]